Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This reflects a minor update to the page's metadata rather than changes to the study details.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s revision tag was updated to v3.6.5, replacing the previous v3.6.4 to reflect a new page version. This change does not modify study data or other critical content.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the site content. This appears to be a metadata/version-control change rather than a modification to the study details or user-facing information.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page revision was updated to v3.6.3, replacing the previous v3.6.2. This indicates a minor update to the page’s documentation or formatting rather than changes to the study content.SummaryDifference0.1%

- Check79 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, indicating a small publication/backend update without changes to the study details.SummaryDifference0.1%

- Check93 days agoChange DetectedThe study page now indicates that enrollment is closed with a 'No longer looking for participants' note, and new help/navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study) while the Intervention/Treatment header formatting was adjusted and the revision version updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.